Scientific article
English

Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue

Published inJournal of controlled release, vol. 52, no. 1, p. 205-213
Publication date1998
Abstract

In recent years peptides and proteins have received much attention as candidate drugs. For many peptides, particularly hormones, it is desirable to release the drug continuously at a controlled rate over a period of weeks or even months. Polylactic acid and poly(lactic-co-glycolic) acid are well known biocompatible biodegradable materials with wide applications including the design of controlled-release systems for pharmaceutical agents. Polylactic acid implants containing vapreotide were prepared by an extrusion method and drug release was evaluated in vivo in rats using an RIA method The development of an injectable, biodegradable depot formulation of a somatostatin analogue (vapreotide) is described which ensures satisfactory peptide blood level in rats over ~250 days. A modification of this formulation by means of a wear coating allows minimisation of the initial burst a feature rarely discussed.

Keywords
  • Polylactic acid
  • Poly(lactic-co-glycolic) acid
  • Controlled release system
  • Vapreotide
  • Burst effect
  • In vivo release
  • Implant
Citation (ISO format)
ROTHEN-WEINHOLD, Alexandra Laurence et al. Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue. In: Journal of controlled release, 1998, vol. 52, n° 1, p. 205–213. doi: 10.1016/S0168-3659(97)00216-2
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0168-3659
225views
0downloads

Technical informations

Creation13/03/2023 15:27:00
First validation13/03/2023 15:27:00
Update16/03/2023 10:58:04
Status update16/03/2023 10:58:04
Last indexation01/11/2024 04:32:17
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack